Pipeline — registered trials by phase
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
— · MASH - Metabolic Dysfunction-Associated Steatohepatitis · Not Yet Recruiting · est. 2027-11
Rezdiffra Pregnancy and Lactation Registry
— · MASH - Metabolic Dysfunction-Associated Steatohepatitis · Recruiting · est. 2030-04-08
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
— · Healthy · Completed · est. 2015-10
Resmetirom in Patients With MASH and HFpEF
— · MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF) · Not Yet Recruiting · est. 2027-11
Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
— · Drug Safety · Completed · est. 2011-10
Drug Interaction Study of MGL-3196 With Atorvastatin
— · Healthy · Completed · est. 2016-05
Drug Interaction Study of MGL-3196 With Pioglitazone
— · Healthy · Completed · est. 2018-12-11
Drug Interaction Study of MGL-3196 With Clopidogrel
— · Healthy · Completed · est. 2019-08-30
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
— · Renal Impairment · Completed · est. 2024-09-16
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
— · Drug Safety · Completed · est. 2012-11
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
— · Healthy · Completed · est. 2017-09-03
Bioavailability Study of MGL-3196 Tablets Compared to Capsules
— · Healthy · Completed · est. 2018-02-17
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
— · Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver · Completed · est. 2021-08-04
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
— · Non-alcoholic Steatohepatitis · Completed · est. 2017-10-25
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
— · MASH - Metabolic Dysfunction-Associated Steatohepatitis · Recruiting · est. 2028-08
Study of Resmetirom in Children and Adolescents With MASH
— · MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis · Recruiting · est. 2029-07
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
— · Heterozygous Familial Hypercholesterolemia · Completed · est. 2018-01-15
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
— · NASH - Nonalcoholic Steatohepatitis · Active Not Recruiting · est. 2028-01
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
— · Non-Alcoholic Fatty Liver Disease · Active Not Recruiting · est. 2027-03
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
— · Non-Alcoholic Fatty Liver Disease · Completed · est. 2023-01-06
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
— · NASH, Cirrhosis, Liver · Active Not Recruiting · est. 2026-12
RezdiffraResmetirom
Source: ClinicalTrials.gov (trials where Madrigal is lead sponsor; 21 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-12Current report (material event)
- 10-Q2026-07-30Quarterly report
- 8-K2026-07-30Current report (material event)
- SCHEDULE 13G/A2026-07-29SCHEDULE 13G/A
- S-82026-06-17Employee stock plan
- 8-K2026-06-17Current report (material event)
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- 10-Q2026-05-06Quarterly report
- 8-K2026-05-06Current report (material event)
- 8-K2026-04-28Current report (material event)
- ARS2026-04-28Annual report to holders
- DEFA14A2026-04-28DEFA14A
- DEF 14A2026-04-28Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 10-K2026-02-19Annual report
- 8-K2026-02-19Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 8-K2026-01-30Current report (material event)
- SCHEDULE 13D/A2025-12-12SCHEDULE 13D/A
- SCHEDULE 13D/A2025-12-12SCHEDULE 13D/A
- 8-K2025-12-11Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 10-Q2025-11-04Quarterly report
- 8-K2025-11-04Current report (material event)
- S-82025-09-11Employee stock plan
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 10-Q2025-08-05Quarterly report
- 8-K2025-08-05Current report (material event)
- 8-K2025-07-30Current report (material event)
- 8-K2025-07-22Current report (material event)
- S-82025-06-20Employee stock plan
- 8-K2025-06-20Current report (material event)
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- 10-Q2025-05-01Quarterly report
- 8-K2025-05-01Current report (material event)
- ARS2025-04-29Annual report to holders
- DEFA14A2025-04-29DEFA14A
- DEF 14A2025-04-29Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.